The Minister of Indigenous Services, Mandy Gull-Masty said the changes to S-2 should not have been made without a lengthy, in ...

ModeX Therapeutics initiates patient dosing in phase 1 trial of MDX2301 for the prevention of Covid-19: Weston, Massachusetts Thursday, April 9, 2026, 18:00 Hrs [IST] ModeX Therap ...

Chief Scientific Officer, Robert Allen, Ph.D., presented as part of the “Antibodies for Infectious Disease Workshop” at the World Vaccine ...

Confirmed, pooled, blinded COVID-19 events in the ongoing Phase 3 DECLARATION study of VYD2311 accumulated to date (~ 50% of study progress) can ...

Researchers found that FcγR signaling in microglia may drive neuron loss in Parkinson’s disease models. Blocking FcγR ...

L1, termed IB101, which was found to form a defined binding pocket that precisely positions the active moiety in a reactive conformation.

A team led by principal investigators Bobo Dang and Ting Zhou at Westlake University/Westlake Laboratory have developed a ...

ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that the first participants have been dosed in a Phase 1 clinical trial ...

Invivyd Inc. IVVD shares are up during Thursday’s premarket session as the company announced progress in its REVOLUTION ...

Based on this concept, the team developed a high-throughput platform that combines yeast surface display with chemoselective protein modification to screen diverse crosslinkers and millions of protein ...